ifi-Institut für interdisziplinäre Medizin
Research facility
Location:
Hamburg,
Germany (DE)
ISNI: -
ROR: https://ror.org/03tr83233
Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018)
Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al.
Conference contribution
Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018)
Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al.
Conference contribution